Neurotrack, a Palo Alto, Calif. and Cambridge, Mass.-based provider of technology that can aid in the diagnosis of Alzheimer’s disease, raised $2m in Series A funding.
The round was led by Founders Fund http://www.foundersfund.com with participation from The Social+Capital Partnership and other angel investors.
The company intends to use the funds to further develop and commercialize its technology.
Founded in 2012 by Elli Kaplan, CEO, Neurotrack develops behavioral biomarkers to assist with the diagnosis of Alzheimer’s disease.
The company holds an exclusive license for the technology behind its behavioral visual cognitive test (sensitive to damage in brain) from Emory University, following the favorable outcome of an NIH-sponsored longitudinal study.
The initial market will be pharmaceuticals seeking to identify individuals in the prodromal (early) phase of Alzheimer’s disease for clinical trials of early stage Alzheimer’s therapies.